Gilead submits hep C drug sofosbuvir for FDA approval

04/9/2013 | American City Business Journals · RTT News

Gilead Sciences filed a new drug application with the FDA for sofosbuvir, an oral nucleotide analogue, to treat chronic hepatitis C virus infection. The firm seeks to use sofosbuvir in combination with existing treatments ribavirin and pegylated interferon in treatment-naive patients with genotype 1, 4, 5 and 6 infection. The drug is expected to be approved by year-end or early next year.

View Full Article in:

American City Business Journals · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations